authors
- Fizazi, K
- Hotte, Sebastien
- Saad, F
- Alekseev, B
- Matveev, VB
- Flechon, A
- Gravis, G
- Joly, F
- Chi, KN
- Malik, Z
- Stewart, P
- Jacobs, C
- Beer, TM
genitourinary tumours, prostate Final overall survival (OS) from the AFFINITY phase 3 trial of custirsen and cabazitaxel/prednisone in men with previously treated metastatic castration-resistant prostate cancer (mCRPC)
Conferences
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- October 2016
has subject area
- 1112 Oncology and Carcinogenesis (FoR)
- Oncology & Carcinogenesis (Science Metrix)
published in
- Annals of Oncology Journal